Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | FCER2 | P06734 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | IL1RN | P18510 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484086 | 0.93 | FCER2 (0.53) | FCER2MMP1CTSLIL1RNERAP2 | |
| SCHEMBL29484083 | 0.93 | FCER2 (0.53) | FCER2MMP1CTSLIL1RNERAP2 | |
| Trifluoroacetic Acid SCHEMBL30164220 | 0.92 | PTPN1 (0.54) | PTPN1FCER2MMP1CTSC | |
| Trifluoroacetic Acid SCHEMBL29484056 | 0.91 | MME (0.56) | — | |
| Trifluoroacetic Acid SCHEMBL28505206 | 0.87 | MMP2 (0.57) | PTPN1CTSLIL1RNERAP2ERAP1 | |
| Trifluoroacetic Acid SCHEMBL29484051 | 0.86 | ALDH1A1 (0.58) | — | |
| Trifluoroacetic Acid SCHEMBL28520566 | 0.86 | MMP2 (0.56) | PTPN1CTSLIL1RNERAP2ERAP1 | |
| SCHEMBL22925587 | 0.84 | CTSC (0.60) | FCER2MMP1CTSC | |
| SCHEMBL22649189 | 0.84 | CTSC (0.60) | FCER2MMP1CTSC | |
| SCHEMBL10049933 | 0.84 | CTSC (0.60) | FCER2MMP1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | PTPN1 4629/4885FCER2 4440/4885MMP1 4797/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | PTPN1 4560/4885FCER2 3360/4885MMP1 4362/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | PTPN1 4584/4885FCER2 4752/4885MMP1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.